Search Results - "Dusheiko, G."

Current and future directions for the management of hepatitis B by Dusheiko, G

“…Hepatitis B virus vaccination, while effective in reducing incident chronic hepatitis B in endemic regions, will not have the desired impact on the rates of…”
Get full text

Side effects of α interferon in chronic hepatitis C by Dusheiko, G

“…Alpha interferons have been used widely to treat chronic hepatitis C virus infection. These include recombinant interferons, purified natural leukocyte, and…”
Get full text

A Shift in Thinking to Reduce Mother-to-Infant Transmission of Hepatitis B by Dusheiko, G

“…(N Engl J Med. 2018;378:952–953)In this editorial, the author discusses a recent study regarding the use of tenofovir disoproxil fumarate (TDF) prophylaxis and…”
Get full text

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg‐positive patients treated with nucleos(t)ide analogues by Wang, B., Carey, I., Bruce, M., Montague, S., Dusheiko, G., Agarwal, K.

“…Summary HBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or…”
Get full text

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference by Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., Colombo, M., Delarocque-Astagneau, E., Dusheiko, G., Esmat, G., Esteban, R., Goldberg, D., Gore, C., Lok, A. S. F., Manns, M., Marcellin, P., Papatheodoridis, G., Peterle, A., Prati, D., Piorkowsky, N., Rizzetto, M., Roudot-Thoraval, F., Soriano, V., Thomas, H. C., Thursz, M., Valla, D., van Damme, P., Veldhuijzen, I. K., Wedemeyer, H., Wiessing, L., Zanetti, A. R., Janssen, H. L. A.

“…Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the…”
Get full text

Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients by Cure, S., Guerra, I., Dusheiko, G.

“…Summary The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first‐generation protease…”
Get full text

Impact of HIV on Host-Virus Interactions during Early Hepatitis C Virus Infection by Danta, M., Semmo, N., Fabris, P., Brown, D., Pybus, O. G., Sabin, C. A., Bhagani, S., Emery, V. C., Dusheiko, G. M., Klenerman, P.

“…Background. Human immunodeficiency virus (HIV) may influence the outcome and natural history of hepatitis C virus (HCV) infection through an impact on acute…”
Get full text

Acute HCV in HIV-positive individuals - a review by Danta, M, Dusheiko, G M

“…HCV/HIV co-infection is a major public health problem with between 10-25% of HIV-positive individuals infected with HCV. Following the introduction of…”
Get more information

Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis by Ferenci, P, Dusheiko, G

Get more information

Review article: 2014 UK consensus guidelines – hepatitis C management and direct‐acting anti‐viral therapy by Miller, M. H., Agarwal, K., Austin, A., Brown, A., Barclay, S. T., Dundas, P., Dusheiko, G. M., Foster, G. R., Fox, R., Hayes, P. C., Leen, C., Millson, C., Ryder, S. D., Tait, J., Ustianowski, A., Dillon, J. F.

“…Summary Background Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a…”
Get full text

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C by Jacobson, I. M., Pawlotsky, J.-M., Afdhal, N. H., Dusheiko, G. M., Forns, X., Jensen, D. M., Poordad, F., Schulz, J.

“…The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and telaprevir to develop consensus recommendations…”
Get full text

Serum NGAL can act as an early renal safety biomarker during long‐term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B by Carey, I., Byrne, R., Childs, K., Horner, M., Bruce, M., Wang, B., Dusheiko, G., Agarwal, K.

“…Summary Tubular renal toxicity is a side‐effect of long‐term therapy with nucleos(t)ide analogue(s) (NA) in chronic hepatitis B (CHB). There are no established…”
Get full text

Current treatment of hepatitis B by Dusheiko, G, Antonakopoulos, N

Get more information

Higher and rising prevalence and incidence of renal impairment and chronic kidney disease in chronic hepatitis B patients compared to matched non-chronic hepatitis B controls in the United States: results of a real-world analysis by Nguyen, M.H, Lim, J, Liou, I, Ozbay, A.B, Fraysse, J, Meyer, N, Dusheiko, G, Gordon, S

Get full text

Advancing age and comorbidities in chronic hepatitis B patients: results of 10-year longitudinal analysis of a diverse population-based cohort of 44,026 chronic hepatitis B patients in the United States by Nguyen, M.H, Lim, J, Ozbay, A.B, Fraysse, J, Liou, I, Meyer, N, Dusheiko, G, Gordon, S

Get full text

Long-term follow up of pan-genotypic hepatitis B e antigen positive patients: factors for seroconversion and effects of treatment by Wang, B, Carey, I, Spaan, M, Horner, M, Bruce, M, Gonsalkorala, E, Dusheiko, G, Agarwal, K

Get full text

Outcome in chronic hepatitis delta: differences between African and non-African patients by Spaan, M, Carey, I, Wang, B, Shang, D, Horner, M, Bruce, M, Dusheiko, G, Agarwal, K

Get full text

Prevalence of osteoporosis and bone fracture was 2-fold higher in chronic hepatitis B compared to non-chronic hepatitis B patients and continued to increase in the last decade: results of a United States population-based cohort study by Gordon, S.C, Lim, J, Liou, I, Ozbay, A.B, Moore-Schiltz, L, Dusheiko, G, Nguyen, M.H

Get full text

3 times higher healthcare cost in chronic hepatitis B patients compared to non-chronic hepatitis B controls especially those with decompensated liver disease: United States real world healthcare utilization and cost analysis by Nguyen, M.H, Lim, J, Ozbay, A.B, Shreay, S, Liou, I, Meyer, N, Dusheiko, G, Gordon, S

Get full text

Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States by Lim, J, Nguyen, M, Liou, I, Ozbay, A.B, Moore-Schiltz, L, Dusheiko, G, Gordon, S

Get full text